Moderate to Severe Atopic Dermatitis Pipeline Analysis Report 2026

Report Coverage

The Moderate to Severe Atopic Dermatitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into moderate to severe atopic dermatitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for moderate to severe atopic dermatitis. The moderate to severe atopic dermatitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The moderate to severe atopic dermatitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with moderate to severe atopic dermatitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to moderate to severe atopic dermatitis.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Moderate to Severe Atopic Dermatitis Pipeline Outlook

Moderate to severe atopic dermatitis is a chronic inflammatory skin disorder characterized by persistent itching, dryness, redness, and recurrent lesions. It occurs when impaired skin-barrier function and immune system dysregulation increase inflammation and sensitivity. Genetic, environmental, and immunological factors can contribute to disease development, progression, and recurrent flare-ups.

Moderate to severe atopic dermatitis is treated with topical corticosteroids, calcineurin inhibitors, biologic therapies, oral or injectable immunomodulators, and other targeted treatments to reduce inflammation, relieve itching, restore skin-barrier function, control flares, and support long-term disease management. In December 2024, the Food and Drug Administration approved Nemluvio (nemolizumab-ilto) for patients aged 12 years and older with moderate to severe atopic dermatitis inadequately controlled by topical prescription therapies. The approval was supported by ARCADIA 1 and ARCADIA 2 trials, which demonstrated improvements in Investigator’s Global Assessment success and Eczema Area and Severity Index-75.

Moderate to Severe Atopic Dermatitis Epidemiology

Epidemiological trends continue to support demand for moderate to severe atopic dermatitis therapies. According to the National Eczema Association, approximately 16.5 million U.S. adults have atopic dermatitis, including 6.6 million with moderate to severe disease. In 2026, Jonathan I. Silverberg et al. reported pediatric prevalence ranging from 9.8% in the United States to 20.1% in Brazil, demonstrating substantial geographic variation. These prevalence patterns highlight a significant patient population and a continued need for effective therapies, supporting ongoing clinical development and pipeline expansion.

Moderate to Severe Atopic Dermatitis – Pipeline Therapeutic Assessment

Moderate to Severe Atopic Dermatitis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to Expert Market Research's analysis, phase II covers a major share of the total Moderate to Severe Atopic Dermatitis clinical trials, accounts for 46%. Phase III at 36%, phase I representing 14% and phase IV accounts for 4%. The strong presence of phase II and phase III candidates indicates an active development landscape, supporting the expansion of treatment options, accelerating innovation, and strengthening future growth opportunities in the moderate to severe atopic dermatitis market.

Moderate to Severe Atopic Dermatitis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the moderate to severe atopic dermatitis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The moderate to severe atopic dermatitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for moderate to severe atopic dermatitis. Janus kinase 1 inhibitors are emerging as targeted therapies for moderate to severe atopic dermatitis. For instance, Ivarmacitinib, a selective oral Janus kinase 1 inhibitor, demonstrated significant improvements in Investigator Global Assessment and Eczema Area and Severity Index outcomes in a Phase 3 clinical trial. Its favorable safety profile further supports its potential as a treatment option for moderate to severe atopic dermatitis.

Moderate to Severe Atopic Dermatitis Clinical Trials – Key Players

The EMR report for the moderate to severe atopic dermatitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed moderate to severe atopic dermatitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in moderate to severe atopic dermatitis clinical trials:

• Shanghai Longwood Biopharmaceuticals Co., Ltd.
• Akeso
• Apogee Therapeutics, Inc.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Shanghai Mabgeek Biotech. Co. Ltd.
• Guangzhou JOYO Pharma Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Nektar Therapeutics
• TRex Bio, Inc.
• Keymed Biosciences Co. Ltd.
• Aclaris Therapeutics, Inc.

Moderate to Severe Atopic Dermatitis – Emerging Drugs Profile

Key Questions Answered in the Moderate to Severe Atopic Dermatitis Pipeline Insight Report

• Which companies/institutions are leading the moderate to severe atopic dermatitis drug development?
• Which company is leading the moderate to severe atopic dermatitis pipeline development activities?
• What is the current moderate to severe atopic dermatitis commercial assessment?
• What are the opportunities and challenges present in the moderate to severe atopic dermatitis pipeline landscape?
• What is the efficacy and safety profile of moderate to severe atopic dermatitis pipeline drugs?
• Which company is conducting major trials for moderate to severe atopic dermatitis drugs?
• Which companies/institutions are involved in moderate to severe atopic dermatitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in moderate to severe atopic dermatitis?

Reasons To Buy This Report

The Moderate to Severe Atopic Dermatitis pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for moderate to severe atopic dermatitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into moderate to severe atopic dermatitis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Moderate to Severe Atopic Dermatitis Epidemiology Forecast

Atopic Dermatitis Market